• Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report.
    • di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, Laganà M, Grisanti S, Cosentini D, Berruti A.
    • Front Oncol. 2023 Feb 20;13:1139372. doi: 10.3389/fonc.2023.1139372.
    • Diagnosis, Management, and Surveillance for Patients with PALB2, CHEK2, and ATM Gene Mutations.
    • Fencer MG, Krupa KA, Bleich GC, Grumet S, Eladoumikdachi FG, Kumar S, Kowzun MJ, Potdevin LB.
    • Clin Breast Cancer. 2023 Feb 15:S1526-8209(23)00034-4. doi: 10.1016/j.clbc.2023.02.004. Epub ahead of print.
    • Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
    • Rosado MM, Pioli C.
    • Cancers (Basel). 2023 Feb 8;15(4):1093. doi: 10.3390/cancers15041093.
    • 2022 : nouvelles pratiques thérapeutiques en oncologie mammaire [2022: New therapeutic practices in breast oncology].
    • Deluche E, Verret B.
    • Bull Cancer. 2023 Feb 7:S0007-4551(23)00036-X. French. doi: 10.1016/j.bulcan.2023.01.002. Epub ahead of print.
    • Review. [Article in French]
    • Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
    • Liede A, Sebby W, Miriyala AKR, Potluri R, Mazumder D, Ghosh A, Papademetriou E, Kilpatrick R, Tyczynski JE.
    • BMC Cancer. 2023 Jan 24;23(1):78. doi: 10.1186/s12885-023-10554-6.
    • Oncologic Safety of Nipple-Sparing Mastectomy for Breast Cancer in BRCA Gene Mutation Carriers: Outcomes at 70 Months Median Follow-Up.
    • Webster AJ, Shanno JN, Santa Cruz HS, Kelly BN, Garstka M, Henriquez A, Specht MC, Gadd MA, Verdial FC, Nguyen A, Oseni TO, Coopey SB, Smith BL.
    • Ann Surg Oncol. 2023 Jan 5. doi: 10.1245/s10434-022-13006-w. Epub ahead of print.
    • Effectiveness of Secondary Risk-Reducing Strategies in Patients With Unilateral Breast Cancer With Pathogenic Variants of BRCA1 and BRCA2 Subjected to Breast-Conserving Surgery: Evidence-Based Simulation Study.
    • Maksimenko J, Rodrigues PP, Nakazawa-Miklaševiča M, Pinto D, Miklaševičs E, Trofimovičs G, Gardovskis J, Cardoso F, Cardoso MJ.
    • JMIR Form Res. 2022 Dec 29;6(12):e37144. doi: 10.2196/37144.
    • A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests.
    • Dehar N, Abedin T, Tang P, Bebb G, Cheung WY.
    • Curr Oncol. 2022 Dec 16;29(12):9916-9927. doi: 10.3390/curroncol29120780.
    • Clinicopathological features, genetic alterations, and BRCA1 promoter methylation in Japanese male patients with breast cancer.
    • Shimomura A, Yoshida M, Kubo T, Yamashita S, Noguchi E, Nagayama A, Hanamura T, Okazaki M, Mukohara T, Tsuruga A, Tanaka K, Kawamura Y, Higuchi T, Takahashi Y, Kurozumi S, Hayashida T, Ichikawa H, Ushijima T, Suto A.
    • Breast Cancer Res Treat. 2022 Dec 9. doi: 10.1007/s10549-022-06822-x. Epub ahead of print.
    • Sociodemographic, Clinical, and Variation Outcomes for Breast Cancer and Breast Cancer-Related Mutations in a Ten-Year Cohort From Neiva, Huila, Colombia.
    • Olaya J, Sanjuan J, Torres-Lopez D, Olaya L, Gutierrez-Vargas M, Olaya G, Olaya JD.
    • Cureus. 2022 Dec 6;14(12):e32257. doi: 10.7759/cureus.32257.
    • Adolescent triple-negative breast cancer with germline pathogenic variants in both BRCA1 and TP53 genes: A case report.
    • Chen D, Zhang C, Yuan M, Zhang Y, Liu Q, Wan D.
    • Front Oncol. 2022 Nov 28;12:970641. doi: 10.3389/fonc.2022.970641.
    • Impact of totally implanted venous access port placement on body image in women with breast cancer.
    • Pizzuti G, Cassani C, Bottazzi A, Ruggieri A, Della Valle A, Dionigi F, Anghelone CAP, Sgarella A, Ferrari A.
    • J Vasc Access. 2022 Nov 18:11297298221136330. doi: 10.1177/11297298221136330. Epub ahead of print.
    • Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers.
    • Sibilio A, Curcio A, Toesca A, Rossi EMC, Corso G.
    • Curr Opin Oncol. 2022 Nov 1;34(6):614-622. doi: 10.1097/CCO.0000000000000872. Epub 2022 Sep 27.
    • Review
    • Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial.
    • Loap P, Loirat D, Berger F, Rodrigues M, Bazire L, Pierga JY, Vincent-Salomon A, Laki F, Boudali L, Raizonville L, Mosseri V, Jochem A, Eeckhoutte A, Diallo M, Stern MH, Fourquet A, Kirova Y.
    • JAMA Oncol. 2022 Oct 27. doi: 10.1001/jamaoncol.2022.5074. Epub ahead of print.

    •• Identifier: NCT03109080: Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC) (RadioPARP). (ClinicalTrials.gov . Accessed 2022 Oct 31.)

    • Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study.
    • Shirota H, Komine K, Takahashi M, Takahashi S, Miyauchi E, Niizuma H, Tada H, Shimada M, Niihori T, Aoki Y, Sugiyama I, Kawamura M, Yasuda J, Suzuki S, Iwaya T, Saito M, Saito T, Shibata H, Furukawa T, Ishioka C.
    • Cancer Med. 2022 Oct 17. doi: 10.1002/cam4.5349. Epub ahead of print.
    • Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients.
    • Dogan I, Aydin E, Yazici H, Saip P.
    • Eur J Breast Health. 2022 Oct 1;18(4):323-328. doi: 10.4274/ejbh.galenos.2022.2022-5-2.
    • Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.
    • McGuire KP, Arthur DW, Mamounas EP.
    • Ann Surg Oncol. 2022 Oct;29(11):6504-6507. doi: 10.1245/s10434-022-12048-4. Epub 2022 Jun 18.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Guideline:

    Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.

    • Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D.
    • Graffeo R, Rana HQ, Conforti F, Bonanni B, Cardoso MJ, Paluch-Shimon S, Pagani O, Goldhirsch A, Partridge AH, Lambertini M, Garber JE.
    • Breast. 2022 Oct;65:32-40. doi: 10.1016/j.breast.2022.06.003. Epub 2022 Jun 18.
    • Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations.
    • Siegmund SE, Manning DK, Davineni PK, Dong F.
    • Mod Pathol. 2022 Oct;35(10):1458-1467. doi: 10.1038/s41379-022-01083-x. Epub 2022 Jul 28.
    • Identification of Shared Neoantigens in BRCA1-Related Breast Cancer.
    • Ruangapirom L, Sutivijit N, Teerapakpinyo C, Mutirangura A, Doungkamchan C.
    • Vaccines (Basel). 2022 Sep 22;10(10):1597. doi: 10.3390/vaccines10101597.
    • Breast cancer in a teenage girl with BRCA mutation: A case report from a low middle-income country.
    • Vohra LM, Ali D, Hashmi SA, Angez M.
    • Int J Surg Case Rep. 2022 Sep;98:107513. doi: 10.1016/j.ijscr.2022.107513. Epub 2022 Aug 13.
    • Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.
    • Baranwal A, Hahn CN, Shah MV, Hiwase DK.
    • Curr Hematol Malig Rep. 2022 Aug 20. doi: 10.1007/s11899-022-00676-2. Epub ahead of print.
    • Review
    • Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    • Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, Bidard FC, Richard F, Yang WW, Steele RE, Pettitt SJ, Van Ongeval C, De Schepper M, Isnaldi E, Nevelsteen I, Smeets A, Punie K, Voorwerk L, Wildiers H, Floris G, Vincent-Salomon A, Derksen PWB, Neven P, Senkus E, Sawyer E, Kok M, Desmedt C.
    • Ann Oncol. 2022 Aug;33(8):769-785. doi: 10.1016/j.annonc.2022.05.006. Epub 2022 May 21.
    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • High grade acinic cell carcinoma of the breast with clear cytoplasm mimics clear cell carcinoma in a BRCA1 mutation carrier: a case report and review of the literature on the molecular analysis.
    • Min L, Qiao H, Hongkai Z.
    • Histol Histopathol. 2022 Jul 27:18501. doi: 10.14670/HH-18-501. Epub ahead of print.
    • Outcomes of non-metastatic triple negative breast cancers: Real-world data from a large Indian cohort.
    • Bajpai J, Kashyap L, Vallathol DH, Das A, Singh M, Pathak R, Rath S, Sekar A, Mohanta S, Reddy A, Joshi S, Nandhana R, Ravind R, Wadasadawala T, Nair N, Ghosh J, Parmar V, Gulia S, Desai S, Shet T, Thakur M, Patil A, Sarin R, Gupta S, Badwe R.
    • Breast. 2022 Jun;63:77-84. doi: 10.1016/j.breast.2022.03.011. Epub 2022 Mar 19.
    • Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients.
    • Espinel W, Champine M, Hampel H, Jeter J, Sweet K, Pilarski R, Pearlman R, Shane K, Brock P, Westman JA, Kipnis L, Sotelo J, Chittenden A, Culver S, Stopfer JE, Schneider KA, Sacca R, Koeller DR, Gaonkar S, Vaccari E, Kane S, Michalski ST, Yang S, Nielsen SM, Bristow SL, Lincoln SE, Nussbaum RL, Esplin ED.
    • Cancers (Basel). 2022 May 13;14(10):2426. doi: 10.3390/cancers14102426.
    • BRCA2-associated Breast Cancer in Transgender Women: Reconstructive Challenges and Literature Review.
    • Cole NA, Copeland-Halperin LR, Shank N, Shankaran V.
    • Plast Reconstr Surg Glob Open. 2022 Apr 22;10(4):e4059. doi: 10.1097/GOX.0000000000004059.
    • Choroidal Metastasis With Secondary Retinal Detachment in a Man With BCRA2-Associated Breast Adenocarcinoma.
    • Sanayei N, Davoudi S, Port A, Chen X.
    • Cureus. 2022 Apr 18;14(4):e24243. doi: 10.7759/cureus.24243.
    • Male Breast Cancer: From Molecular Genetics to Clinical Management.
    • Pensabene M, Von Arx C, De Laurentiis M.
    • Cancers (Basel). 2022 Apr 15;14(8):2006. doi: 10.3390/cancers14082006.
    • The Impact of BRCA Status on Therapy Choices.
    • Schapira L, Tung N.
    • Medscape. 2022 Apr 12.
    • Familial breast cancer, pregnancy and cardiotoxicity associated with the use of doxorubicin and reaction with trastuzumab.
    • Valente PMS, Gomes MCB, Martins WA, Castilho SR.
    • J Oncol Pharm Pract. 2022 Mar 23:10781552221080081. doi: 10.1177/10781552221080081. Epub ahead of print.
    • Case report
    • BRCA1 Mutation: An Insidious Enemy with Multiple Facets….
    • Godin P, Duhoux FP, Mazzeo F, Rojas M, Bollue E, François A, Galant C, Coulie J, Coyette M, Lentini A, Deswisen Y, Perlepe V, Fellah L, Leconte I, Berlière M.
    • Case Rep Oncol. 2022 Mar 14;15(1):238-244. doi: 10.1159/000521840.
    • Axillary lymphadenopathy in a high-risk breast screening patient following the COVID-19 vaccine: a diagnostic conundrum.
    • Musaddaq B, Brown A, Dluzewski S, Marafioti T, Malhotra A.
    • BJR Case Rep. 2022 Mar 9;7(6):20210063. doi: 10.1259/bjrcr.20210063.
    • Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.
    • Layman RM, Lin H, Gutierrez Barrera AM, Karuturi MS, Yam C, Arun BK.
    • Cancer Med. 2022 Mar;11(6):1474-1483. doi: 10.1002/cam4.4566. Epub 2022 Feb 6.
    • [A Case of Breast Cancer during Pregnancy Treated with Neoadjuvant Chemotherapy during Pregnancy].
    • Okujima K, Aoki R, Takemoto K, Takaoka M, Kusakabe E, Shidahara T, Noda H, Taguchi K, Nishiyama K, Murakami A, Yamashita M, Kamei Y, Takada Y.
    • Gan To Kagaku Ryoho. 2022 Mar;49(3):289-292. Japanese.
    • Case report. [Article in Japanese]
    • Hereditary Breast and Ovarian Cancer: An Updated Primer for OB/GYNs.
    • Bellcross CA.
    • Obstet Gynecol Clin North Am. 2022 Mar;49(1):117-147. doi: 10.1016/j.ogc.2021.11.005.
    • Review
    • Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis.
    • Nara M, Ishihara S, Kitano A, Tamura N, Aruga T, Kobayashi D, Nakamura S, Yamauchi H.
    • Breast Cancer. 2022 Feb 25. doi: 10.1007/s12282-022-01343-3. Epub ahead of print.
    • Meta-Analysis
    • The CHEK2*1100delC Mutation and Adolescent Breast Cancer: A Case Report of Breast Cancer in a 19-Year-Old and a Review of the Literature.
    • Soleimani T, Engwall AJ, Bourdon C, Torabi MA, Fortes T.
    • Breast Care (Basel). 2022 Feb;17(1):85-89. doi: 10.1159/000513679. Epub 2021 Mar 8.
    • Case report
    • Remote AI Supported E-Multidisciplinary Oncology Conference in Breast Cancer as a Technology and Method to Optimize Outcomes in the Peripheries.
    • Mammas CS, Mamma AS, Papaxoinis G, Georgiou I.
    • Stud Health Technol Inform. 2022 Jan 14;289:309-312. doi: 10.3233/SHTI210921.
    • Germline variant of BRCA1 c.5332G>A has clinical features of hereditary breast and ovarian cancer syndrome.
    • Saita C, Aruga T, Adachi M, Kumaki Y, Iwamoto N, Yonekura R, Nakatsugawa N, Inokuchi T, Ishiba T, Honda Y, Yamaguchi T.
    • Int Cancer Conf J. 2021 Sep 22 [2022 Jan];11(1):12-16. doi: 10.1007/s13691-021-00512-z.
    • Metastatic ovarian carcinoma in breast cancer patients during risk-reducing salpingo-oophorectomy: Report of two cases.
    • Shakya P, Bajracharya A, Shrestha S, Kharel S, Maharjan R, Shrestha AK.
    • Ann Med Surg (Lond). 2021 Dec 6;73:103158. doi: 10.1016/j.amsu.2021.103158. eCollection 2022 Jan.
    • BRCA1 and Metastasis: Outcome of Defective DNA Repair.
    • Krishnan R, Patel PS, Hakem R.
    • Cancers (Basel). 2021 Dec 27;14(1):108. doi: 10.3390/cancers14010108.
    • The Role of US in Depicting Axillary Metastasis in High-Risk Breast Cancer Patients.
    • Pintican R, Duma MM, Szep M, Feier D, Eniu D, Goidescu I, Chiorean A.
    • J Pers Med. 2021 Dec 16;11(12):1379. doi: 10.3390/jpm11121379.
    • [A Case of Recurrent Breast Cancer with Improving Activities of Daily Living by Olaparib Treatment].
    • Nakagawa T, Oda G, Okamoto K, Ishikawa T, Wakana K, Oshima N.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1556-1558. Japanese.
    • Case report. [Article in Japanese]
    • [Two Cases of Hereditary Breast Cancer in Which Genetic Counseling Was Useful].
    • Sasaki A, Nagata T, Okamoto Y, Watanabe M, Saida Y.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1589-1591. Japanese.
    • Case report. [Article in Japanese]
    • [A Case of Metastatic Breast Cancer with BRCA1 Mutation after Breast Reconstruction and Pregnancy].
    • Suzuki T, Hashimoto N, Yokoyama K, Yoshida T, Yamauchi Y, Sawano T, Ohashi M, Kimura A, Kato M, Umehara Y, Murata A, Takahash K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1840-1842. Japanese.
    • Case report. [Article in Japanese]
    • [Hereditary Breast and Ovarian Cancer(HBOC)in a Young Adult-A Case Report].
    • Adachi K, Kubota H, Suzuki S, Hirano T, Ishibashi N, Sakurai K.
    • Gan To Kagaku Ryoho. 2021 Dec;48(13):1843-1845. Japanese.
    • Case report. [Article in Japanese]
    • Recreational Physical Activity and Outcomes After Breast Cancer in Women at High Familial Risk.
    • Kehm RD, MacInnis RJ, John EM, Liao Y, Kurian AW, Genkinger JM, Knight JA, Colonna SV, Chung WK, Milne R, Zeinomar N, Dite GS, Southey MC, Giles GG, McLachlan SA, Whitaker KD, Friedlander ML, Weideman PC, Glendon G, Nesci S; kConFab Investigators, Phillips KA, Andrulis IL, Buys SS, Daly MB, Hopper JL, Terry MB.
    • JNCI Cancer Spectr. 2021 Dec;5(6):pkab090. doi: 10.1093/jncics/pkab090.
    • A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2.
    • Kitahara M, Hozumi Y, Machinaga M, Hayashi Y.
    • Case Rep Oncol. 2021 Nov 18;14(3):1645-1651. doi: 10.1159/000520148.
    • Suggested Modifications to the Management of Patients With Breast Cancer During the COVID-19 Pandemic: Web-Based Survey Study.
    • Elsamany S, Elbaiomy M, Zeeneldin A, Tashkandi E, Hassanin F, Abdelhafeez N, O Al-Shamsi H, Bukhari N, Elemam O.
    • JMIR Cancer. 2021 Nov 15;7(4):e27073. doi: 10.2196/27073.
    • Breast cancer characteristics and surgery among women with Li-Fraumeni syndrome in Germany-A retrospective cohort study.
    • Rippinger N, Fischer C, Sinn HP, Dikow N, Sutter C, Rhiem K, Grill S, Cremer FW, Nguyen HP, Ditsch N, Kast K, Hettmer S, Kratz CP, Schott S.
    • Cancer Med. 2021 Nov;10(21):7747-7758. doi: 10.1002/cam4.4300. Epub 2021 Sep 26.
    • Breast Cancer Drug Approvals Issued by EMA: A Review of Clinical Trials.
    • Duranti S, Fabi A, Filetti M, Falcone R, Lombardi P, Daniele G, Franceschini G, Carbognin L, Palazzo A, Garganese G, Paris I, Scambia G, Pietragalla A.
    • Cancers (Basel). 2021 Oct 16;13(20):5198. doi: 10.3390/cancers13205198.
    • The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.
    • Greer AC, Lanes A, Poorvu PD, Kennedy P, Thomas AM, Partridge AH, Ginsburg ES.
    • Cancer. 2021 Oct 15;127(20):3872-3880. doi: 10.1002/cncr.33601. Epub 2021 Jun 23.
    • Prognostic Prediction of BRCA Mutations by 18F-FDG PET/CT SUVmax in Breast Cancer.
    • Özdemir S, Silan F, Akgün MY, Araci N, Çirpan I, Koç Öztürk F, Özdemir Ö.
    • Mol Imaging Radionucl Ther. 2021 Oct 15;30(3):158-168. doi: 10.4274/mirt.galenos.2021.82584.
    • De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence.
    • Conte B, Soldato D, Razeti MG, Fregatti P, de Azambuja E, Schettini F, Prat A, Del Mastro L, Lambertini M.
    • Clin Breast Cancer. 2021 Oct 8:S1526-8209(21)00292-5. doi: 10.1016/j.clbc.2021.10.001. Epub ahead of print.
    • Review
    • Unique challenges and outcomes of young women with breast cancers from a tertiary care cancer centre in India.
    • Bajpai J, Ventrapati P, Joshi S, Wadasadawala T, Rath S, Pathak R, Nandhana R, Mohanty S, Chougle Q, Engineer M, Abraham N, Ghosh J, Nair N, Gulia S, Popat P, A P, Sheth T, Desai S, Thakur M, Rangrajan V, Parmar V, Sarin R, Gupta S, Badwe RA.
    • Breast. 2021 Oct 6;60:177-184. doi: 10.1016/j.breast.2021.09.008. Epub ahead of print.
    • Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges.
    • El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB.
    • Hosp Pract (1995). 2021 Sep 22:1-5. doi: 10.1080/21548331.2021.1974678. Epub ahead of print.
    • Commentary
    • "High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis".
    • Shraga S, Grinshpun A, Zick A, Kadouri L, Cohen Y, Maimon O, Adler-Levy Y, Zeltzer G, Granit A, Maly B, Carmon E, Meiner V, Sella T, Hamburger T, Peretz T.
    • Front Oncol. 2021 Sep 2;11:683656. doi: 10.3389/fonc.2021.683656.
    • Multiple Mutation Detection for Risk Assessment in Patients with Breast Cancer by Using Next-Generation Sequencing.
    • Liu PF, Zhuo ZL, Xie F, Xian HP, Liu C, Wang S, Zhao XT.
    • Ann Clin Lab Sci. 2021 Sep;51(5):670-677.
    • A Cost Decision Model Supporting Treatment Strategy Selection in BRCA1/2 Mutation Carriers in Breast Cancer.
    • Carbonara N, La Forgia D, Pellegrino R, Ressa C, Tommasi S.
    • J Pers Med. 2021 Aug 27;11(9):847. doi: 10.3390/jpm11090847.
    • A rare case of breast cancer in a transgender woman.
    • Sieberg R, Soriano K, Zuurbier R.
    • Radiol Case Rep. 2021 Aug 26;16(11):3285-3288. doi: 10.1016/j.radcr.2021.07.052.
    • The change in incidence of breast cancer by stage: how is it changed after the COVID-19 pandemic? A single-center retrospective study.
    • Citgez B, Yigit B, Ucak R, Kaya C, Tufan AE, Yetkin SG.
    • Ann Ital Chir. 2021;92:488-493. [Epub 2021 Aug 20.]
    • Heart Rate Variability-Guided Exercise During Chemotherapy in Triathlete with Stage 1 BRCA1-Mutated Breast Cancer.
    • Talbot A, McCabe M, Daly B, Gallagher D.
    • Ir Med J. 2021 Aug 19;114(7):420.
    • Venous thromboembolism incidence in cancer patients with germline BRCA mutations.
    • Muñoz AJ, de Toro M, Ortega L, López C, Gutiérrez A, Juliao DS, Arregui M, Lobato N, Echavarría I, Márquez-Rodas I, Martín M.
    • Clin Transl Oncol. 2021 Aug 9. doi: 10.1007/s12094-021-02678-7. Epub ahead of print.
    • Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    • Kurian AW, Abrahamse P, Bondarenko I, Hamilton AS, Deapen D, Gomez SL, Morrow M, Berek JS, Hofer TP, Katz SJ, Ward KC.
    • J Natl Cancer Inst. 2021 Aug 9:djab151. doi: 10.1093/jnci/djab151. Epub ahead of print.
    • PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
    • Bosnjak M, Jesenko T, Markelc B, Janzic L, Cemazar M, Sersa G.
    • Bioelectrochemistry. 2021 Aug;140:107832. doi: 10.1016/j.bioelechem.2021.107832. Epub 2021 May 1. Erratum in: Bioelectrochemistry. 2021 Oct;141:107865.
    • Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
    • Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2021 Aug;23(8):1416-1423. doi: 10.1038/s41436-021-01151-8. Epub 2021 May 11.
    • Guidelines
    • Ultrasound guided needle biopsy of axilla to evaluate nodal metastasis after preoperative systemic therapy in cohort of 106 breast cancers enriched with BRCA1/2 pathogenic variant carriers.
    • Licite B, Irmejs A, Maksimenko J, Loža P, Trofimovics G, Miklaševics E, Nazarovs J, Romanovska M, Deicmane J, Irmejs R, Purkalne G, Gardovskis J.
    • Hered Cancer Clin Pract. 2021 Jul 7;19(1):30. doi: 10.1186/s13053-021-00187-w.
    • Ovarian metastasis from breast cancer mimicking a primary ovarian neoplasm: A case report.
    • Akizawa Y, Kanno T, Horibe Y, Shimizu Y, Noguchi E, Yamamoto T, Okamoto T, Nagashima Y, Tabata T.
    • Mol Clin Oncol. 2021 Jul;15(1):135. doi: 10.3892/mco.2021.2297. Epub 2021 May 17. PMID: 34055350; PMCID: PMC8145603.
    • Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?
    • Dunn C, Gately L, Gibbs P.
    • JAMA Oncol. 2021 Jun 17. doi: 10.1001/jamaoncol.2021.1904. Epub ahead of print.
    • Letter, Comment

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Original research:

    Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.

    • A clinical case of diagnosis of breast cancer in patients with family history of BRCA mutations 1.
    • Aitmagambetova M, Smagulova G, Bekmukhambetov Y, Zavalyonnaya O, Tulyaeva A.
    • Rep Pract Oncol Radiother. 2021 Jun 9;26(3):463-469. doi: 10.5603/RPOR.a2021.0069.
    • Oncological Follow-up with 2-[18F]-FDG PET/CT in Li-Fraumeni Syndrome.
    • Hernandez MA, Vega Gonzalez IF, Vélez LL, Arango CM.
    • Mol Imaging Radionucl Ther. 2021 Jun 3;30(2):110-112. doi: 10.4274/mirt.galenos.2020.33255.
    • Breast Cancer in Togolese Women: Imaging and Clinicopathological Findings.
    • Darré T, Tchaou M, Djiwa T, Douaguibe B, Bassowa A, Adani-Ifé S, Amavi AK, N'Timon B, Amadou A, Simgban P, N'Bortche BK, Amégbor K, Aboubakari AS, Napo-Koura G.
    • Breast Cancer (Auckl). 2021 May 30;15:11782234211020242. doi: 10.1177/11782234211020242.
    • Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.
    • Ben David MA, Evron E, Rasco AF, Shai A, Corn BW.
    • Cancers (Basel). 2021 May 30;13(11):2694. doi: 10.3390/cancers13112694.
    • Pathology of Breast Cancer Metastasis and A View of Metastasis to The Brain.
    • Sakibuzzaman M, Mahmud S, Afroze T, Fathma S, Zakia UB, Afroz S, Zafar F, Hossain M, Barua A, Akter S, Chowdhury HI, Ahsan E, Eshan SH, Fariza TT.
    • Int J Neurosci. 2021 May 27:1-18. doi: 10.1080/00207454.2021.1935929. Epub ahead of print.
    • Review
    • OHSU to Expand Tumor Board Program After Seeing Benefits in Breast Cancer Patients.
    • Kanski A.
    • Precision Oncology News. Disease Areas. 2021 May 24.
    • Risk-Adjusted Prevention. Perspectives on the Governance of Entitlements to Benefits in the Case of Genetic (Breast Cancer) Risks.
    • Meier F, Harney A, Rhiem K, Neusser S, Neumann A, Braun M, Wasem J, Huster S, Dabrock P, Schmutzler RK.
    • Recent Results Cancer Res. 2021 [First Online: 22 May 2021];218:47-66. doi: 10.1007/978-3-030-63749-1_5.
    • eBook chapter
    • Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity.
    • Phung TN, Webster TH, Lenkiewicz E, Malasi S, Andreozzi M, McCullough AE, Anderson KS, Pockaj BA, Wilson MA, Barrett MT.
    • Sci Rep. 2021 May 19;11(1):10571. doi: 10.1038/s41598-021-90170-1.
    • Breast Cancer Adjuvant Radiotherapy in BRCA1/2, TP53, ATM Genes Mutations: Are There Solved Issues?
    • Lazzari G, Buono G, Zannino B, Silvano G.
    • Breast Cancer (Dove Med Press). 2021 May 12;13:299-310. doi: 10.2147/BCTT.S306075.
    • Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
    • Zheng Y, Li B, Pan D, Cao J, Zhang J, Wang X, Li X, Hou W, Bao D, Ren L, Yang J, Wang S, Qiu Y, Zhou F, Liu Z, Zhu S, Zhang L, Qing T, Wang Y, Yu Y, Wu J, Hu X, Shi L.
    • Breast Cancer Res. 2021 May 1;23(1):53. doi: 10.1186/s13058-021-01428-5.
    • The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and/or fertility preservation strategies in premenopausal women with early breast cancer.
    • Blondeaux E, Massarotti C, Fontana V, Poggio F, Arecco L, Fregatti P, Bighin C, Giannubilo I, Ruelle T, Razeti MG, Boni L, Anserini P, Del Mastro L, Lambertini M.
    • Front Oncol. 2021 Apr 26;10:690320. doi: 10.3389/fonc.2021.690320.
    • A case of hereditary metachronous bilateral triple-negative breast cancer that was highly sensitive to carboplatin.
    • Wu R, Adachi K, Koyama Y, Orimoto K, Okazaki M, Asaoka M, Teraoka S, Ueda A, Miyahara K, Kawate T, Kaise H, Yamada K, Sato E, Ishikawa T.
    • J Surg Case Rep. 2021 Apr 14;2021(4):rjab018. doi: 10.1093/jscr/rjab018.
    • Management and outcomes of men diagnosed with primary breast cancer.
    • Johnson AE, Coopey SB, Spring LM, Horick NK, Leone JP, Lin NU, Dominici LS, Hughes KS, Jimenez RB.
    • Breast Cancer Res Treat. 2021 Apr 8. doi: 10.1007/s10549-021-06174-y. Epub ahead of print.
    • An overview on breast cancer genetics and recent innovations: Literature survey.
    • Ramya Sree PR, Thoppil JE.
    • Breast Dis. 2021 Apr 7. doi: 10.3233/BD-201040. Epub ahead of print.
    • Review
    • The management of menopausal symptoms in women following treatment for cancer at a specialist menopause service.
    • Chakrabarti R, Holloway D, Bruce D, Rymer J.
    • Post Reprod Health. 2021 Apr 7:20533691211000548. doi: 10.1177/20533691211000548. Epub ahead of print.
    • Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
    • Wan Q, Su L, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
    • JAMA Netw Open. 2021 Apr 1;4(4):e216259. doi: 10.1001/jamanetworkopen.2021.6259.

    Commentary:

    Mastectomy or Breast-Conserving Therapy for BRCA1/2 Variant Carriers.

    • Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
    • Cobain EF, Wu YM, Vats P, Chugh R, Worden F, Smith DC, Schuetze SM, Zalupski MM, Sahai V, Alva A, Schott AF, Caram MEV, Hayes DF, Stoffel EM, Jacobs MF, Kumar-Sinha C, Cao X, Wang R, Lucas D, Ning Y, Rabban E, Bell J, Camelo-Piragua S, Udager AM, Cieslik M, Lonigro RJ, Kunju LP, Robinson DR, Talpaz M, Chinnaiyan AM.
    • JAMA Oncol. 2021 Apr 1;7(4):525-533. doi: 10.1001/jamaoncol.2020.7987.

    Editorial:

    Precision Medicine in Oncology-Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations.

    Letter, Comment:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?

    Letter, Reply:

    Is Universal Next-Generation Sequencing Testing of Patients With Advanced Cancer Ready for Prime Time?-Reply.

    Press: Germline Testing: Variant in 1 in 6 Cases of Advanced Cancer. (Medscape Oncology)

    • Tumor phenotype and concordance in synchronous bilateral breast cancer in young women.
    • Pak LM, Gaither R, Rosenberg SM, Ruddy KJ, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Warner E, Snow C, Collins LC, King TA, Partridge AH.
    • Breast Cancer Res Treat. 2021 Apr;186(3):815-821. doi: 10.1007/s10549-020-06027-0. Epub 2020 Nov 26.
    • Bilateral nipple-sparing mastectomy and breast reconstruction in BRCA1 mutation-positive simultaneous bilateral breast cancer: A case study.
    • Yoneyama K, Nakagawa M, Hara A.
    • Int J Surg Case Rep. 2021 Apr;81:105788. doi: 10.1016/j.ijscr.2021.105788. Epub 2021 Mar 17.
    • A male with primary accessory breast carcinoma in an axilla is strongly suspected of having hereditary breast cancer.
    • Takahashi E, Terata K, Nanjo H, Ishiyama K, Hiroshima Y, Yamaguchi A, Yatsuyanagi M, Kudo C, Wakita A, Takashima S, Sato Y, Imai K, Motoyama S, Minamiya Y.
    • Int Cancer Conf J. 2021 Jan 10;10(2):107-111. doi: 10.1007/s13691-020-00466-8. eCollection 2021 Apr.
    • Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts.
    • Martin M, Ramos-Medina R, Bernat R, García-Saenz JA, Del Monte-Millan M, Alvarez E, Cebollero M, Moreno F, Gonzalez-Haba E, Bueno O, Romero P, Massarrah T, Echavarria I, Jerez Y, Herrero B, Gonzalez Del Val R, Lobato N, Rincon P, Palomero MI, Marquez-Rodas I, Lizarraga S, Asensio F, Lopez-Tarruella S.
    • Sci Rep. 2021 Mar 29;11(1):7064. doi: 10.1038/s41598-021-85962-4.
    • Delineation of an unknown significance FANCA genetic variant in a recurrent breast cancer patient.
    • Kastora S, Triantafyllidou O, Kounidas G, Vlahos N.
    • BMJ Case Rep. 2021 Mar 24;14(3):e241251. doi: 10.1136/bcr-2020-241251.
    • Case report
    • Variations in breast cancer surgical treatment and timing: determinants and disparities.
    • Dankwa-Mullan I, George J, Roebuck MC, Tkacz J, Willis VC, Reyes F, Arriaga YE.
    • Breast Cancer Res Treat. 2021 Mar 10. doi: 10.1007/s10549-021-06155-1. Epub ahead of print.
    • Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    • Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD, Turnbull C, Hanson H, Narod S, Arun BK, Aapro MS, Mandel JL, Normanno N, Lambrechts D, Vergote I, Anahory M, Baertschi B, Baudry K, Bignon YJ, Bollet M, Corsini C, Cussenot O, De la Motte Rouge T, Duboys de Labarre M, Duchamp F, Duriez C, Fizazi K, Galibert V, Gladieff L, Gligorov J, Hammel P, Imbert-Bouteille M, Jacot W, Kogut-Kubiak T, Lamy PJ, Nambot S, Neuzillet Y, Olschwang S, Rebillard X, Rey JM, Rideau C, Spano JP, Thomas F, Treilleux I, Vandromme M, Vendrell J, Vintraud M, Zarca D, Hughes KS, Alés Martínez JE.
    • Eur J Cancer. 2021 Feb 9;146:30-47. doi: 10.1016/j.ejca.2020.12.023. Epub ahead of print.
    • DNA damage response inhibitors: An avenue for TNBC treatment.
    • Jin J, Tao Z, Cao J, Li T, Hu X.
    • Biochim Biophys Acta Rev Cancer. 2021 Feb 5:188521. doi: 10.1016/j.bbcan.2021.188521. Epub ahead of print.
    • Review
    • Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
    • Tsai ML, Knaack M, Martone P, Krueger J, Baldinger SR, Lillemoe TJ, Susnik B, Grimm E, Olet S, Rueth N, Swenson KK.
    • Clin Breast Cancer. 2021 Feb;21(1):47-56. doi: 10.1016/j.clbc.2020.07.003. Epub 2020 Jul 9.
    • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.
    • Inuzuka M, Watanabe C, Yokoyama S, Kuwayama T, Akashi-Tanaka S, Arai M, Nakamura S; Registration Committee of the Japanese HBOC consortium.
    • Clin Breast Cancer. 2021 Feb;21(1):e48-e52. doi: 10.1016/j.clbc.2020.08.004. Epub 2020 Aug 20.
    • Utilization, Timing, and Outcomes of BRCA Genetic Testing Among Women With Newly Diagnosed Breast Cancer From a National Commercially Insured Population: The ABOARD Study.
    • Armstrong J, Lynch K, Virgo KS, Schwartz MD, Friedman S, Dean M, Andrews JE, Bourquardez Clark E, Clasen J, Conaty J, Parrillo O, Sutphen R.
    • JCO Oncol Pract. 2021 Feb;17(2):e226-e235. doi: 10.1200/OP.20.00571.
    • Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
    • Cho EJ, Kim JK, Baek HJ, Kim SE, Park EJ, Choi BK, Kim TH, Shin DH, Lim YK, Deng CX, Kim SS.
    • Int J Biol Sci. 2021 Jan 31;17(3):689-701. doi: 10.7150/ijbs.53667.
    • Triple-Negative Breast Cancer and the COVID-19 Pandemic: Clinical Management Perspectives and Potential Consequences of Infection.
    • Brown JM, Wasson MD, Marcato P.
    • Cancers (Basel). 2021 Jan 15;13(2):296. doi: 10.3390/cancers13020296.
    • Challenges and Considerations on Risk-Reducing Surgery in BRCA1/2 Patients with Advanced Breast Cancer.
    • Vasconcelos de Matos L, Fernandes L, Louro P, Plácido A, Barros M, Vaz F.
    • Curr Oncol. 2021 Jan 14;28(1):485-490. doi: 10.3390/curroncol28010050.
    • Estimation of healthcare-related charges in women with BRCA mutations and breast cancer.
    • Biskupiak J, Unni S, Telford C, Yoo M, Ye X, Deka R, Brixner D, Stenehjem D.
    • BMC Health Serv Res. 2021 Jan 13;21(1):58. doi: 10.1186/s12913-020-06038-z.
    • Coffee consumption and breast cancer risk: a narrative review in the general population and in different subtypes of breast cancer.
    • Nehlig A, Reix N, Arbogast P, Mathelin C.
    • Eur J Nutr. 2021 Jan 13. doi: 10.1007/s00394-020-02465-0. Epub ahead of print.
    • Review
    • American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline for Management of Hereditary Breast Cancer.
    • Yip CH, Newman LA.
    • JAMA Surg. 2021 Jan 13. doi: 10.1001/jamasurg.2020.6254. Epub ahead of print.
    • Guideline
    • Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer.
    • Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A.
    • Front Oncol. 2021 Jan 11;10:574813. doi: 10.3389/fonc.2020.574813.
    • BRCA testing and outcomes in women with breast cancer.
    • Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE.
    • Breast Cancer Res Treat. 2021 Jan 3. doi: 10.1007/s10549-020-06038-x. Epub ahead of print.
    • Breast reconstruction in patients with BRCA mutation and breast cancer - our approach.
    • Ventruba Tomáš, Brancíková Dagmar, Ventruba Pavel, Minár Luboš, Felsinger Michal, Vomela Jindrich.
    • Ceska Gynekol. 2021;86(6):374-380. English. doi: 10.48095/cccg2021374.
    • Surgical Treatment after Neoadjuvant Systemic Therapy in Young Women with Breast Cancer: Results from a Prospective Cohort Study.
    • Kim HJ, Dominici L, Rosenberg SM, Zheng Y, Pak LM, Poorvu PD, Ruddy KJ, Tamimi R, Schapira L, Come SE, Peppercorn J, Borges VF, Warner E, Vardeh H, Collins LC, Gaither R, King TA, Partridge AH.
    • Ann Surg. 2020 Dec 23;Publish Ahead of Print. doi: 10.1097/SLA.0000000000004296. Epub ahead of print.
    • Germline TP53 Testing in Breast Cancers: Why, When and How?
    • Evans DG, Woodward ER, Bajalica-Lagercrantz S, Oliveira C, Frebourg T.
    • Cancers (Basel). 2020 Dec 14;12(12):3762. doi: 10.3390/cancers12123762.
    • Biomarkers in Her2- Positive Disease.
    • Klocker EV, Suppan C.
    • Breast Care (Basel). 2020 Dec;15(6):586-593. doi: 10.1159/000512283. Epub 2020 Oct 28.
    • [Selection of Operative Procedure for Breast Cancer in Carriers of BRCA VUS in Japan].
    • Kakimoto M, Asai D, Akamine K, Kobayashi R, Yamazaki N, Morimoto Y, Kubo K, Yamada N, Kobayashi A, Ogata K, Hasegawa K.
    • Gan To Kagaku Ryoho. 2020 Dec;47(13):2092-2094.
    • [Article in Japanese]
    • Locoregional treatments and ipsilateral breast cancer recurrence rates in BRCA1/2 mutation carriers.
    • Bernstein-Molho R, Laitman Y, Galper S, Jacobson G, Boursi B, Gal-Yam EN, Kaufman B, Friedman E, Kaidar-Person O.
    • Int J Radiat Oncol Biol Phys. 2020 Nov 28:S0360-3016(20)34598-3. doi: 10.1016/j.ijrobp.2020.11.058. Epub ahead of print.
    • New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
    • Han Y, Yu X, Li S, Tian Y, Liu C.
    • Front Oncol. 2020 Nov 25;10:578095. doi: 10.3389/fonc.2020.578095.
    • Clinical outcomes of patients after nipple-sparing mastectomy and reconstruction based on the expander/implant technique.
    • Toh U, Takenaka M, Iwakuma N, Akagi Y.
    • Surg Today. 2020 Nov 13. doi: 10.1007/s00595-020-02175-4. Epub ahead of print.
    • An ATM Gene Mutation Caused My Breast Cancer
    • Cohen E.
    • FORCE. Blog. 2020 Nov 12.
    • Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays.
    • Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Karkhaneh Yousefi N, Azari T, Zaki-Dizaji M.
    • Biol Proced Online. 2020 Oct 1;22:23. doi: 10.1186/s12575-020-00133-5.
    • Was ist neu bei der Diagnostik und Therapie des Mammakarzinoms? – Aktuelle Standards in der Behandlung von Brustkrebs [Breast cancer - state of the art - Short overview of the current standard of treatment].
    • Albert A, Stüber T, Bauer J, Wöckel A.
    • Dtsch Med Wochenschr. 2020 Oct;145(20):1460-1463. German. doi: 10.1055/a-1026-3620. Epub 2020 Oct 6.
    • Review, [Article in German]
    • Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Katz SJ.
    • JNCI Cancer Spectr. 2020 Sep 18;5(1):pkaa083. doi: 10.1093/jncics/pkaa083.
    • Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
    • Green RF, Kumerow MT, Rodriguez JL, Addie S, Beachy SH, Senier L.
    • Public Health Genomics. 2020 Sep 17:1-12. doi: 10.1159/000510336. Epub ahead of print.

    Original research:

    Proposed outcomes measures for state public health genomic programs.

    • Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer.
    • Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J, Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB; kConFab Investigators, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ; HEBON Investigators, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN; SWE-BRCA Investigators, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H.
    • NPJ Breast Cancer. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6.
    • Hereditary breast cancer: translation into clinical practice of recent American Society of Clinical Oncology, American Society of Radiation Oncology, and Society of Surgical Oncology recommendations.
    • Corso G, Magnoni F.
    • Eur J Cancer Prev. 2020 Sep 3. doi: 10.1097/CEJ.0000000000000624. Epub ahead of print.
    • Review
    • Sentinel lymph node biopsy should be considered for clinically node-negative breast cancer regardless of BRCA1/2 mutation status.
    • Huang X, Liu JQ, Zhou YD, Xu Y, Chen C, Wang X, Cao X, Yao R, Sun Q.
    • Ann Transl Med. 2020 Sep;8(18):1183. doi: 10.21037/atm-20-5996.
    • Nipple-sparing mastectomy with immediate breast reconstruction - early complications and outcomes of the treatment.
    • Bocian A, Kedzierawski P, Kurczych K, Jasnowski P, Maliszewski D, Kolacinska A.
    • Prz Menopauzalny. 2020 Sep;19(3):117-122. doi: 10.5114/pm.2020.99618. Epub 2020 Oct 2.
    • Male Breast Cancer in Togo: Imaging and Clinicopathological Findings.
    • Darre T, Tchaou M, Djiwa T, Simgban P, Amavi AK, N'Timon B, Amadou A, Bombonne M, Sama B, Amégbor K, Napo-Koura G.
    • Int J Breast Cancer. 2020 Aug 31;2020:3056067. doi: 10.1155/2020/3056067.
    • Management of early breast cancer during the COVID-19 pandemic in Brazil.
    • Cavalcante FP, Novita GG, Millen EC, Zerwes FP, de Oliveira VM, Sousa ALL, Freitas Junior R.
    • Breast Cancer Res Treat. 2020 Aug 16. doi: 10.1007/s10549-020-05877-y. Epub ahead of print.
    • Breast imaging, breast surgery, and cancer genetics in the age of COVID-19.
    • Yin K, Singh P, Drohan B, Hughes KS.
    • Cancer. 2020 Aug 4. doi: 10.1002/cncr.33113. Epub ahead of print.
    • Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.
    • Peleg Hasson S, Menes T, Sonnenblick A.
    • Pharmgenomics Pers Med. 2020 Jul 27;13:227-238. doi: 10.2147/PGPM.S233485.
    • Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.
    • Printz C.
    • Cancer. 2020 Jul 1;126(13):2955. doi: 10.1002/cncr.32999.

    Original research:

    Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.

    • ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.
    • Trombetta MG, Dragun A, Mayr NA, Pierce LJ.
    • Pract Radiat Oncol. 2020 Jul-Aug;10(4):235-242. doi: 10.1016/j.prro.2020.04.003. Epub 2020 May 21.

    Guideline:

    Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.

    • Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
    • Tung NM, Boughey JC, Pierce LJ, Robson ME, Bedrosian I, Dietz JR, Dragun A, Gelpi JB, Hofstatter EW, Isaacs CJ, Jatoi I, Kennedy E, Litton JK, Mayr NA, Qamar RD, Trombetta MG, Harvey BE, Somerfield MR, Zakalik D.
    • J Clin Oncol. 2020 Jun 20;38(18):2080-2106. doi: 10.1200/JCO.20.00299. Epub 2020 Apr 3.

    Summary, Review:

    Management of Hereditary Breast Cancer: ASCO, ASTRO, and SSO Guideline.

    Summary, Review:

    ASTRO Radiation Therapy Summary of the ASCO-ASTRO-SSO Guideline on Management of Hereditary Breast Cancer.

    Commentary, Review:

    Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

    • Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig? [Targeted Therapy in Metastatic Breast Cancer-Which Molecular Tests Are Necessary?].
    • Schmidt M.
    • J Gynakol Endokrinol. 2020 Jun 2:1-3. German. doi: 10.1007/s41974-020-00141-z. Epub ahead of print.
    • Breast-conserving therapy is safe both within BRCA1/2 mutation carriers and noncarriers with breast cancer in the Chinese population.
    • Huang X, Cai XY, Liu JQ, Hao WW, Zhou YD, Wang X, Xu Y, Chen C, Lin Y, Wang CJ, Song Y, Sun Q.
    • Gland Surg. 2020 Jun;9(3):775-787. doi: 10.21037/gs-20-531.
    • Genetic Factors in the Locoregional Management of Breast Cancer.
    • Haffty BG, Euhus DM, Pierce LJ.
    • J Clin Oncol. 2020 May 22:JCO1902859. doi: 10.1200/JCO.19.02859. Epub ahead of print.
    • Review
    • Paraneoplastic dermatomyositis in hereditary breast and ovarian cancer syndrome.
    • Kumar N, Deo S.
    • Breast J. 2020 May 18. doi: 10.1111/tbj.13888. Epub ahead of print.
    • Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
    • Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, Bodmer A, Treilleux I, Lang N, Tille JC, Chappuis PO, Buisson A, Giraud S, Lasset C, Bonadona V, Trédan O, Labidi-Galy SI.
    • Sci Rep. 2020 Apr 27;10(1):7073. doi: 10.1038/s41598-020-63759-1.
    • Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency.
    • Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, Cigler T, Robson M, Dickler MN.
    • Fertil Steril. 2020 Apr 21. pii: S0015-0282(20)30036-4. doi: 10.1016/j.fertnstert.2020.01.033. [Epub ahead of print]
    • Young Women With Breast Cancer: Treatment, Care, and Nursing Implications.
    • Corey B, Smania MA, Spotts H, Andersen M.
    • Clin J Oncol Nurs. 2020 Apr 1;24(2):139-147. doi: 10.1188/20.CJON.139-147.
    • Review
    • Bilateral Paget's Disease of the Breast in a Patient with CHEK2 Mutation.
    • Owusu-Brackett N, Menon PD, Nazarullah A, Jatoi I, Elmi M.
    • Eur J Breast Health. 2020 Apr 1;16(2):152-154. doi: 10.5152/ejbh.2020.5568. eCollection 2020 Apr.
    • Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers.
    • McCrorie AD, Ashfield S, Begley A, Mcilmunn C, Morrison PJ, Boyd C, Eccles B, Greville-Heygate S, Copson ER, Cutress RI, Eccles DM, Savage KI, McIntosh SA.
    • J Pathol Clin Res. 2020 Apr;6(2):146-153. doi: 10.1002/cjp2.155. Epub 2020 Feb 5.
    • Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments.
    • Testa U, Castelli G, Pelosi E.
    • Med Sci (Basel). 2020 Mar 23;8(1). pii: E18. doi: 10.3390/medsci8010018.
    • An interesting case of likely BRCA2 related bilateral breast cancer with metastasis in the fimbrial part of fallopian tube.
    • Boltežar L, Gašljevic G, Novakovic S, Stegel V, Škof E.
    • Hered Cancer Clin Pract. 2020 Mar 19;18:7. doi: 10.1186/s13053-020-00139-w. eCollection 2020.
    • Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
    • Li A, Schleicher SM, Andre F, Mitri ZI.
    • Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-14. doi: 10.1200/EDBK_280463.
    • BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies.
    • Lee A, Moon BI, Kim TH.
    • Ann Lab Med. 2020 Mar;40(2):114-121. doi: 10.3343/alm.2020.40.2.114.
    • Review

    Introductory article:

    From Genetic Testing to Treatment and Prevention of BRCA-Related Breast Cancer.

    • Breast Cancer in Men: A Single Center Experience Over a Period of 22 years.
    • Hoffman A, Ben Ishay O, Horesh N, Shabtai M, Forschmidt E, Rosin D, Gutman M, Ram E.
    • Isr Med Assoc J. 2020 Mar;22(3):160-163.
    • Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
    • Kaplan HG, Calip GS, Malmgren JA.
    • Oncologist. 2020 Feb 19. doi: 10.1634/theoncologist.2019-0099. [Epub ahead of print]
    • Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
    • Kurian AW, Ward KC, Abrahamse P, Hamilton AS, Deapen D, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2020 Feb 6:e196400. doi: 10.1001/jamaoncol.2019.6400. [Epub ahead of print]

    Press: Breast Cancer Care After Genetic Testing Often Doesn’t Follow Guidelines. (Clinical OMICs)

    Research news:

    Women with inherited genetic mutations for breast cancer do not always receive treatment according to guidelines.

    • Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy.
    • Pellini F, Granuzzo E, Urbani S, Mirandola S, Caldana M, Lombardi D, Fiorio E, Mandarà M, Pollini GP.
    • Breast Care (Basel). 2020 Feb;15(1):14-20. doi: 10.1159/000501711. Epub 2019 Sep 13.
    • BRCA Mutation Association with Recurrence Score and Discordance in a Large Oncotype Database.
    • Blanter J, Zimmerman B, Tharakan S, Ru M, Cascetta K, Tiersten A.
    • Oncology. 2020 Jan 21:1-4. doi: 10.1159/000504965. [Epub ahead of print]
    • Prognosis of BRCA1/2-negative breast cancer patients with HBOC risk factors compared with sporadic breast cancer patients without HBOC risk factors.
    • Ryu JM, Nam SJ, Kim SW, Lee JE, Chae BJ, Lee SK, Yu J.
    • Jpn J Clin Oncol. 2020 Jan 11. pii: hyz147. doi: 10.1093/jjco/hyz147. [Epub ahead of print]
    • Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Surgical Results From the BrighTNess Randomized Clinical Trial.
    • Golshan M, Loibl S, Wong SM, Houber JB, O'Shaughnessy J, Rugo HS, Wolmark N, McKee MD, Maag D, Sullivan DM, Metzger-Filho O, Von Minckwitz G, Geyer CE Jr, Sikov WM, Untch M.
    • JAMA Surg. 2020 Jan 8:e195410. doi: 10.1001/jamasurg.2019.5410. [Epub ahead of print]
    • Comparison of clinical features and oncologic outcomes between familial (non-hereditary) and hereditary breast cancer in Korean female patients.
    • Park CS, Park HY, Jung JH, Kim WW, Chae YS, Lee SJ, Park JY, Park JY, Lee J.
    • Asian J Surg. 2020 Jan 7. pii: S1015-9584(19)30880-2. doi: 10.1016/j.asjsur.2019.12.001. [Epub ahead of print]
    • Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation.
    • Ye F, Huang L, Lang G, Hu X, Di G, Shao Z, Cao A.
    • Cancer Med. 2020 Jan 7. doi: 10.1002/cam4.2836. [Epub ahead of print]
    • SEOM clinical guidelines in hereditary breast and ovarian cancer (2019).
    • González-Santiago S, Ramón Y Cajal T, Aguirre E, Alés-Martínez JE, Andrés R, Balmaña J, Graña B, Herrero A, Llort G, González-Del-Alba A; SEOM Hereditary Cancer Working Group.
    • Clin Transl Oncol. 2019 Dec 30. doi: 10.1007/s12094-019-02262-0. [Epub ahead of print]
    • Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy.
    • Dubois C, Martin F, Hassel C, Magnier F, Daumar P, Aubel C, Guerder S, Mounetou E, Penault-Lorca F, Bamdad M.
    • J Clin Med. 2019 Dec 26;9(1). pii: E64. doi: 10.3390/jcm9010064.
    • The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient's perspective.
    • Sidorenkov G, Nagel J, Meijer C, Duker JJ, Groen HJM, Halmos GB, Oonk MHM, Oostergo RJ, van der Vegt B, Witjes MJH, Nijland M, Havenga K, Maduro JH, Gietema JA, de Bock GH.
    • J Transl Med. 2019 Nov 14;17(1):374. doi: 10.1186/s12967-019-2122-x.
    • Invasive bilateral breast cancer and high grade serous ovarian cancer with BRCA1-germline mutation and brainstem metastasis under PARP inhibitors.
    • Zahari MM, Chiorean AR, Duma MM, Ungureanu A, Kacso G.
    • Arch Clin Cases. 2021 [2019?] Oct 27;6(3):69-75. doi: 10.22551/2019.24.0603.10156.
    • Genetic and Genomic Advances in Breast Cancer Diagnosis and Treatment.
    • Walker-Smith TL, Peck J.
    • Nurs Womens Health. 2019 Oct 25. pii: S1751-4851(19)30188-6. doi: 10.1016/j.nwh.2019.09.003. [Epub ahead of print]
    • Review
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    • Song Y, Barry WT, Seah DS, Tung NM, Garber JE, Lin NU.
    • Cancer. 2019 Oct 3. doi: 10.1002/cncr.32540. [Epub ahead of print]
    • Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.
    • Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.
    • Nat Med. 2019 Sep 30. doi: 10.1038/s41591-019-0582-4. [Epub ahead of print]
    • Available and emerging molecular markers in the clinical management of breast cancer.
    • Giridhar KV, Liu MC.
    • Expert Rev Mol Diagn. 2019 Sep 9. doi: 10.1080/14737159.2019.1664901. [Epub ahead of print]
    • Review
    • The Expression Level of BRCA2 and Its Changes during Chemotherapy in Patients with Different Pathological Types of Mammary Cancer.
    • Huang Y, Luo M, Huang J, Huang S, Wei L, Zhang Y, Zhang Z.
    • Iran J Public Health. 2019 Sep;48(9):1654-1662.
    • Framework Ranks 'Actionability' of Genetic Mutations for Precision Medicine.
    • Kerr DJ.
    • Medscape Oncology. 2019 Jul 18.

    Original research:

    Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).

    • The role of BRCA1/2 in hereditary and familial breast and ovarian cancers.
    • Hawsawi YM, Al-Numair NS, Sobahy TM, Al-Ajmi AM, Al-Harbi RM, Baghdadi MA, Oyouni AA, Alamer OM.
    • Mol Genet Genomic Med. 2019 Jul 17:e879. doi: 10.1002/mgg3.879. [Epub ahead of print]
    • Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.
    • Wei M, Maurer KA, Henry NL.
    • Breast J. 2019 Jul 4. doi: 10.1111/tbj.13454. [Epub ahead of print]
    • Case report
    • Can I Keep My Nipple? Factors Influencing the Surgical Decision between Skin-Sparing and Nipple-Sparing Mastectomy.
    • Wang M, Huang J, Chagpar AB.
    • Am Surg. 2019 Jul 1;85(7):768-771.
    • Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers.
    • George A.
    • Curr Genet Med Rep. 2019 Jun;7(2):116-123. doi: 10.1007/s40142-019-00167-6. Epub 2019 May 9.
    • Review
    • Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
    • Schneeweiss A, Denkert C, Fasching PA, Fremd C, Gluz O, Kolberg-Liedtke C, Loibl S, Lück HJ.
    • Geburtshilfe Frauenheilkd. 2019 Jun;79(6):605-617. doi: 10.1055/a-0887-0285. Epub 2019 Jun 14.
    • Male breast cancer: Specific biological characteristics and survival in a Portuguese cohort.
    • André S, Pereira T, Silva F, Machado P, Vaz F, Aparício M, Silva GL, Pinto AE.
    • Mol Clin Oncol. 2019 Jun;10(6):644-654. doi: 10.3892/mco.2019.1841. Epub 2019 Apr 8.
    • Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    • Vallard A, Magné N, Guy JB, Espenel S, Rancoule C, Diao P, Deutsch E, Rivera S, Chargari C.
    • Br J Radiol. 2019 May;92(1097):20170657. doi: 10.1259/bjr.20170657. Epub 2019 Feb 27.
    • Review

    Comment, Letter:

    Implications of the evidence for breast conservation therapy in BRCA-gene mutation carriers.

    • β-hCG induced mutant BRCA1 ignites drug resistance in susceptible breast tissue.
    • Sengodan SK, Hemalatha SK, Nadhan R, Somanathan T, Mathew AP, Chil A, Kopczynski J, Nair RS, Kumar JM, Srinivas P.
    • Carcinogenesis. 2019 Apr 9. pii: bgz070. doi: 10.1093/carcin/bgz070. [Epub ahead of print]
    • Clinical findings and outcomes of MRI staging of breast cancer in a diverse population.
    • Raghavendra A, Wecsler J, Ji L, Sheth P, Ricker C, Church T, Sposto R, Lang J, Sener S, Larsen L, Tripathy D.
    • Breast Cancer Res Treat. 2019 Apr;174(2):315-324. doi: 10.1007/s10549-018-05084-w. Epub 2018 Dec 12.
    • Review
    • Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
    • Condorelli R, Mosele F, Verret B, Bachelot T, Bedard PL, Cortes J, Hyman DM, Juric D, Krop I, Bieche I, Saura C, Sotiriou C, Cardoso F, Loibl S, Andre F, Turner NC.
    • Ann Oncol. 2019 Mar 1;30(3):365-373. doi: 10.1093/annonc/mdz036.

    Commentary: Framework Ranks 'Actionability' of Genetic Mutations for Precision Medicine (Medscape Oncology)

    • Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    • Sønderstrup IMH, Jensen MB, Ejlertsen B, Eriksen JO, Gerdes AM, Kruse TA, Larsen MJ, Thomassen M, Laenkholm AV.
    • Acta Oncol. 2019 Mar;58(3):363-370. doi: 10.1080/0284186X.2018.1539239. Epub 2019 Jan 7.
    • Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
    • Quek RGW, Mardekian J.
    • Adv Ther. 2019 Mar;36(3):708-720. doi: 10.1007/s12325-018-0867-x. Epub 2019 Jan 17.
    • The cost of cancer care and impact of financial hardship on treatment.
    • [No author given]
    • FORCE. XRAYS. 2019 Feb 8.

    Original research:

    BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.

    News: Labs, Advocacy Groups Push Back on Medicare Policy Shift on NGS Testing for Hereditary Cancer Risk. (GenomeWeb)

    News: Pricey Precision Medicine Often Financially Toxic For Cancer Patients. (Kaiser Health News)

    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Treating metastatic breast cancer: Analysis of the impact of palbociclib (Ibrance) on overall survival in the PALOMA-3 trial.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 23.
    • Triple-negative breast cancer: the reality in Chile and in Latin America.
    • Caglevic C, Anabalón J, Soza C, Milla E, Gaete F, Carrasco AM, Panay S, Gallardo C, Mahave M.
    • Ecancermedicalscience. 2019 Jan 22;13:893. doi: 10.3332/ecancer.2019.893. eCollection 2019.
    • Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients.
    • Lambertini M, Di Maio M, Poggio F, Pagani O, Curigliano G, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I.
    • Reprod Biomed Online. 2019 Jan 10. pii: S1472-6483(19)30011-2. doi: 10.1016/j.rbmo.2018.11.031. [Epub ahead of print]
    • Improving outcomes for young women with breast cancer: fertility and childbearing issues.
    • [No author given]
    • FORCE. XRAYS. 2019 Jan 7.

    ClinicalTrials.gov: Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer (POSITIVE) (NIH. ClinicalTrials.gov.)

    • Synchronous Ovarian and Breast Cancers with a Novel Variant in BRCA2 Gene: A Case Report.
    • Llinás-Quintero N, Cabrera-Florez E, Mendoza-Fandiño G, Matute-Turizo G, Vasquez-Trespalacios EM, Gallón-Villegas LJ.
    • Case Rep Oncol Med. 2019 Jan 6;2019:6958952. doi: 10.1155/2019/6958952. eCollection 2019.
    • Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
    • Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS.
    • Cancer Treat Res Commun. 2019;19:100121. doi: 10.1016/j.ctarc.2019.100121. Epub 2019 Feb 6.
    • Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
    • Meijer TG, Verkaik NS, Sieuwerts AM, van Riet J, Naipal KAT, van Deurzen CHM, den Bakker MA, Sleddens HFBM, Dubbink HJ, den Toom TD, Dinjens WNM, Lips E, Nederlof PM, Smid M, van de Werken HJG, Kanaar R, Martens JWM, Jager A, van Gent DC.
    • Clin Cancer Res. 2018 Dec 15;24(24):6277-6287. doi: 10.1158/1078-0432.CCR-18-0063. Epub 2018 Aug 23.
    • BRCA1 Mutations Associated With Increased Risk of Brain Metastases in Breast Cancer: A 1: 2 Matched-pair Analysis.
    • Zavitsanos PJ, Wazer DE, Hepel JT, Wang Y, Singh K, Leonard KL.
    • Am J Clin Oncol. 2018 Dec;41(12):1252-1256. doi: 10.1097/COC.0000000000000466.
    • [Breast cancer in males, case presentation and literature review.]
    • Fabián-Estrada E, Flores-Rangel GA, Mosiñoz-Montes R, Núñez-Trenado LA, Esparza-García E, Carballido-Barrita CA.
    • Rev Med Inst Mex Seguro Soc. 2018 Nov 30;56(4):424-428.
    • Case report, [Article in Spanish]
    • The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
    • Sorscher S.
    • Oncologist. 2018 Nov;23(11):1266-1268. doi: 10.1634/theoncologist.2017-0681. Epub 2018 Jun 4.
    • Case report
    • Unusual recurrence of breast cancer in a BRCA-variant patient after fat grafting.
    • Skendelas JP, Lee C, Mangino A, Carson WE 3rd.
    • Clin Case Rep. 2018 Oct 31;6(12):2457-2462. doi: 10.1002/ccr3.1861. eCollection 2018 Dec.
    • BRCAness Combined With a Family History of Cancer Is Associated With a Poor Prognosis for Breast Cancer Patients With a High Risk of BRCA Mutations.
    • Mori H, Kubo M, Kai M, Velasquez VV, Kurata K, Yamada M, Okido M, Kuroki S, Oda Y, Nakamura M.
    • Clin Breast Cancer. 2018 Oct;18(5):e1217-e1227. doi: 10.1016/j.clbc.2018.05.008. Epub 2018 Jun 2.
    • Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer.
    • Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D.
    • Clin Breast Cancer. 2018 Oct;18(5):e1229-e1235. doi: 10.1016/j.clbc.2017.12.014. Epub 2017 Dec 30.
    • Breast cancer in transgender patients: A systematic review. Part 1: Male to female.
    • Hartley RL, Stone JP, Temple-Oberle C.
    • Eur J Surg Oncol. 2018 Oct;44(10):1455-1462. doi: 10.1016/j.ejso.2018.06.035. Epub 2018 Jul 25.
    • Review
    • Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    • Yoshimura A, Okumura S, Sawaki M, Hattori M, Ishiguro J, Adachi Y, Kotani H, Gondo N, Kataoka A, Iwase M, Onishi S, Sugino K, Terada M, Horisawa N, Mori M, Takaiso N, Hyodo I, Iwata H.
    • Breast Cancer. 2018 Sep;25(5):539-546. doi: 10.1007/s12282-018-0850-z. Epub 2018 Mar 8.
    • Geographic Variation in Postoperative Imaging for Low-Risk Breast Cancer.
    • Franc BL, Copeland TP, Thombley R, Park M, Marafino B, Dean ML, Boscardin WJ, Rugo HS, Seidenwurm D, Sharma B, Johnston SR, Dudley RA.
    • J Natl Compr Canc Netw. 2018 Jul;16(7):829-837. doi: 10.6004/jnccn.2018.7024.
    • Impact of an embedded genetic counselor on breast cancer treatment.
    • Pederson HJ, Hussain N, Noss R, Yanda C, O'Rourke C, Eng C, Grobmyer SR.
    • Breast Cancer Res Treat. 2018 May;169(1):43-46. doi: 10.1007/s10549-017-4643-4. Epub 2018 Jan 18.
    • Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney.
    • Naher S, Tognela A, Moylan E, Adams DH, Kiely BE.
    • Intern Med J. 2018 May;48(5):567-572. doi: 10.1111/imj.13628.
    • Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review.
    • Sæther NH, Skuja E, Irmejs A, Maksimenko J, Miklasevics E, Purkalne G, Gardovskis J.
    • Hered Cancer Clin Pract. 2018 Apr 27;16:9. doi: 10.1186/s13053-018-0092-2. eCollection 2018.
    • Predictors of survival for breast cancer patients with a BRCA1 mutation.
    • Narod SA, Huzarski T, Gronwald J, Byrski T, Marczyk E, Cybulski C, Szwiec M, Wisniowski R, Birkenfeld B, Kilar E, Sibilski R, Sun P, Lubinski J.
    • Breast Cancer Res Treat. 2018 Apr;168(2):513-521. doi: 10.1007/s10549-017-4605-x. Epub 2017 Dec 15.
    • Germline breast cancer susceptibility gene mutations and breast cancer outcomes.
    • Wang YA, Jian JW, Hung CF, Peng HP, Yang CF, Cheng HS, Yang AS.
    • BMC Cancer. 2018 Mar 22;18(1):315. doi: 10.1186/s12885-018-4229-5.
    • Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers.
    • Gast KC, Viscuse PV, Nowsheen S, Haddad TC, Mutter RW, Wahner Hendrickson AE, Couch FJ, Ruddy KJ.
    • Curr Treat Options Cardiovasc Med. 2018 Mar 1;20(2):18. doi: 10.1007/s11936-018-0609-z.
    • Review
    • Survival and mutation status in breast cancer patients under age 40.
    • [No author given]
    • FORCE. XRAYS. 2018 Feb 15.

    Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    • Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    • Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A.
    • Clin Breast Cancer. 2018 Feb;18(1):e107-e113. doi: 10.1016/j.clbc.2017.07.016. Epub 2017 Aug 1.
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Enhancing radiosensitisation of BRCA2-proficient and BRCA2-deficient cell lines with hyperthermia and PARP1-i.
    • Oei AL, Ahire VR, van Leeuwen CM, Ten Cate R, Stalpers LJA, Crezee J, Kok HP, Franken NAP.
    • Int J Hyperthermia. 2018 Feb;34(1):39-48. doi: 10.1080/02656736.2017.1324642. Epub 2017 May 19.
    • Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    • Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.
    • Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.

    Commentary:

    Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?

    Research news:

    Young women with BRCA mutation can safely postpone radical surgery.

    Press: Survival After Breast Cancer 'Unaffected by BRCA Status' (Medscape)

    Research news: Survival and mutation status in breast cancer patients under age 40. (FORCE: XRAYS)

    • Rationale for Mastectomy after Neoadjuvant Chemotherapy.
    • Gusic LH, Walsh K, Flippo-Morton T, Sarantou T, Boselli D, White RL Jr..
    • Am Surg. 2018 Jan 1;84(1):126-132.
    • A salpingeal carcinoma revealed after prophylactic salpingoophorectomy in an asymptomatic BRCA1 carrier with breast malignancy.
    • Giannos A, Stavrou S, Douskos A, Drakakis P, Loutradis D.
    • Int J Surg Case Rep. 2018;52:107-110. doi: 10.1016/j.ijscr.2018.10.014. Epub 2018 Oct 12.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Clinical Management of Carriers of BRCA Pathogenic Variants. Treatment Strategies. Breast cancer.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform.
    • Lanz HL, Saleh A, Kramer B, Cairns J, Ng CP, Yu J, Trietsch SJ, Hankemeier T, Joore J, Vulto P, Weinshilboum R, Wang L.
    • BMC Cancer. 2017 Nov 2;17(1):709. doi: 10.1186/s12885-017-3709-3.
    • BRCA related breast cancer and sporadic tumors: same prognosis or survivorship bias?
    • Ballatore Z, Bracci R, Bianchi F, Maccaroni E, Belvederesi L, Brugiati C, Murrone A, Pagliaretta S, Pistelli M, Berardi R.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi28. doi: 10.1093/annonc/mdx424.011.
    • Preoperative Panel Testing for Hereditary Cancer Syndromes Does Not Significantly Impact Time to Surgery for Newly Diagnosed Breast Cancer Patients Compared with BRCA1/2 Testing.
    • Murphy AE, Hussain L, Ho C, Dunki-Jacobs E, Lee D, Tameron A, Huelsman K, Rice C, Wexelman BA.
    • Ann Surg Oncol. 2017 Oct;24(10):3055-3059. doi: 10.1245/s10434-017-5957-5. Epub 2017 Aug 1.
    • Prognostic impact of germline mutations in inherited cancer syndromes.
    • Corso G, Feroce I, Intra M, Veronesi P, Sacchini V, Bonanni B, Galimberti V.
    • Future Oncol. 2017 Oct;13(24):2125-2127. doi: 10.2217/fon-2017-0296. Epub 2017 Oct 6.
    • Editorial, Review
    • Final report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology, on a fact-finding questionnaire on the status of treatment of hereditary breast and ovarian cancer syndrome in Japan.
    • Satoh T, Takamatsu K, Takeshima N, Kobayashi H, Aoki D, Suzuki N.
    • J Obstet Gynaecol Res. 2017 Sep;43(9):1377-1380. doi: 10.1111/jog.13409. Epub 2017 Aug 17.
    • Clinical outcomes of female breast cancer according to BRCA mutation status.
    • Cronin-Fenton DP, Kjærsgaard A, Nørgaard M, Pedersen IS, Thomassen M, Kaye JA, Gutierrez L, Telford C, Lewis J, Tyczynski JE, Sørensen HT.
    • Cancer Epidemiol. 2017 Aug;49:128-137. doi: 10.1016/j.canep.2017.05.016. Epub 2017 Jun 8.
    • Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.
    • Dosani M, Schrader KA, Nichol A, Sun S, Shenkier T, Lohn Z, Aubertin G, Tyldesley S.
    • Cureus. 2017 Jul 11;9(7):e1458. doi: 10.7759/cureus.1458.
    • Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer.
    • Gurda GT, Ambros T, Nikiforova MN, Nikiforov YE, Lucas PC, Dabbs DJ, Lee AV, Brufsky AM, Puhalla SL, Bhargava R.
    • Appl Immunohistochem Mol Morphol. 2017 Jul;25(6):392-398. doi: 10.1097/PAI.0000000000000322.
    • Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
    • Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N.
    • J Exp Clin Cancer Res. 2017 Apr 20;36(1):57. doi: 10.1186/s13046-017-0517-1.
    • Role of postmastectomy radiotherapy in early-stage (T1-2N0-1M0) triple-negative breast cancer: a systematic review.
    • Chen F, Pu F.
    • Onco Targets Ther. 2017 Apr 6;10:2009-2016. doi: 10.2147/OTT.S123803. eCollection 2017.
    • Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature.
    • Nandikolla AG, Venugopal S, Anampa J.
    • Breast Cancer (Dove Med Press). 2017 Mar 23;9:207-215. doi: 10.2147/BCTT.S134241. eCollection 2017.
    • Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant.
    • Geurts-Giele WR, van Verschuer VM, van Deurzen CH, van Diest PJ, Pedrosa RM, Collée JM, Koppert LB, Seynaeve C, Dinjens WN.
    • Mod Pathol. 2017 Jan;30(1):15-25. doi: 10.1038/modpathol.2016.145. Epub 2016 Sep 9.
    • Germ line mutations associated with leukemias.
    • Porter CC.
    • Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):302-308.
    • Review
    • When knowledge of a heritable gene mutation comes out of the blue: treatment-focused genetic testing in women newly diagnosed with breast cancer.
    • Meiser B, Quinn VF, Gleeson M, Kirk J, Tucker KM, Rahman B, Saunders C, Watts KJ, Peate M, Geelhoed E, Barlow-Stewart K, Field M, Harris M, Antill YC, Mitchell G.
    • Eur J Hum Genet. 2016 Nov;24(11):1517-1523. doi: 10.1038/ejhg.2016.69. Epub 2016 Jun 22.
    • [A Case of Male Hereditary Breast Cancer Involving a Sentinel Lymph Node Biopsy].
    • Tokunou K, Yamamoto T, Yamamoto H, Kamei R, Kitamura Y, Ando S.
    • Gan To Kagaku Ryoho. 2016 Nov;43(12):2026-2028.
    • Case report [Article in Japanese]
    • Assessing, Counseling, and Treating Patients at High Risk for Breast Cancer.
    • Clifford E, Hughes KS, Roberts M, Pirzadeh-Miller S, McLaughlin SA.
    • Ann Surg Oncol. 2016 Oct;23(10):3128-32. doi: 10.1245/s10434-016-5399-5. Epub 2016 Jul 11.
    • Review
    • Implementation of the 21-gene recurrence score test in the United States in 2011.
    • Lynch JA, Berse B, Petkov V, Filipski K, Zhou Y, Khoury MJ, Hassett M, Freedman AN.
    • Genet Med. 2016 Oct;18(10):982-90. doi: 10.1038/gim.2015.218. Epub 2016 Feb 11.
    • Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer.
    • Hsieh AH, Kichenadasse G, Vatandoust S, Roy A, Sukumaran S, Karapetis CS, Martin H, Chong LC, Koczwara B.
    • Intern Med J. 2016 Oct;46(10):1153-1159. doi: 10.1111/imj.13169.
    • Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer.
    • Cobain EF, Milliron KJ, Merajver SD.
    • Semin Oncol. 2016 Oct;43(5):528-535. doi: 10.1053/j.seminoncol.2016.10.001. Epub 2016 Oct 8.
    • Review
    • Cardiovascular risk of BRCA1/2 mutation carriers: A review.
    • van Westerop LL, Arts-de Jong M, Hoogerbrugge N, de Hullu JA, Maas .
    • Maturitas. 2016 Sep;91:135-9. doi: 10.1016/j.maturitas.2016.06.012. Epub 2016 Jun 22.
    • Review
    • Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
    • Gargiulo P, Pensabene M, Milano M, Arpino G, Giuliano M, Forestieri V, Condello C, Lauria R, De Placido S.
    • BMC Cancer. 2016 Jul 4;16(1):375.
    • The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.
    • Huzarski T, Byrski T, Gronwald J, Cybulski C, Oszurek O, Szwiec M, Gugała K, Stawicka M, Morawiec Z, Mierzwa T, Falco M, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siołek M, Surdyka D, Wiśniowski R, Posmyk M, Domagała P, Sun P, Lubiński J, Narod SA; Polish Breast Cancer Consortium.
    • Breast Cancer Res Treat. 2016 Apr;156(2):371-8. doi: 10.1007/s10549-016-3749-4. Epub 2016 Mar 17.
    • Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
    • Murria Estal R, Palanca Suela S, de Juan Jiménez I, Alenda Gonzalez C, Egoavil Rojas C, García-Casado Z, López Guerrero JA, Juan Fita MJ, Sánchez Heras AB, Segura Huerta Á, Santaballa Bertrán A, Chirivella González I, Llop García M, Pérez Simó G, Barragán González E, Bolufer Gilabert P.
    • Fam Cancer. 2016 Apr;15(2):193-200. doi: 10.1007/s10689-015-9864-2.
    • Epigenetic regulation of ID4 in the determination of the BRCAness phenotype in breast cancer.
    • Branham MT, Campoy E, Laurito S, Branham R, Urrutia G, Orozco J, Gago F, Urrutia R, Roqué M.
    • Breast Cancer Res Treat. 2016 Jan;155(1):13-23. doi: 10.1007/s10549-015-3648-0. Epub 2015 Nov 27.
    • Breast Cancer Experience of the Molecular Tumor Board at the University of California, San Diego Moores Cancer Center.
    • Parker BA, Schwaederlé M, Scur MD, Boles SG, Helsten T, Subramanian R, Schwab RB, Kurzrock R.
    • J Oncol Pract. 2015 Nov;11(6):442-9. doi: 10.1200/JOP.2015.004127. Epub 2015 Aug 4.
    • Immunoprofile from tissue microarrays to stratify familial breast cancer patients.
    • Schirosi L, De Summa S, Tommasi S, Paradiso A, Sambiasi D, Popescu O, Simone G, Mangia A.
    • Oncotarget. 2015 Sep 29;6(29):27865-79. doi: 10.18632/oncotarget.4720.
    • Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse.
    • Stearns V, Park BH.
    • JAMA Oncol. 2015 Aug 1;1(5):569-70. doi: 10.1001/jamaoncol.2015.0761.
    • Breast cancer in pregnancy: an institutional experience.
    • Blanquisett AH, Vicent CH, Gregori JG, Zotano ÁG, Porta VG, Simón AR.
    • Ecancermedicalscience. 2015 Jul 8;9:551. doi: 10.3332/ecancer.2015.551. eCollection 2015.
    • A Rare Case of BRCA2-Associated Breast Cancer in Pregnancy.
    • Leidhin CN, Heeney A, Connolly C, Swan N, Foster A, Geraghty J.
    • Ir Med J. 2015 Jul-Aug;108(7):217-8.
    • AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2015.
    • Hanf V, Schütz F, Liedtke C, Thill M; AGO Breast Committee.
    • Breast Care (Basel). 2015 Jul;10(3):189-97. doi: 10.1159/000431346. Epub 2015 Jun 18.
    • Practice Guideline
    • Health professionals' evaluation of delivering treatment-focused genetic testing to women newly diagnosed with breast cancer.
    • Douma KF, Meiser B, Kirk J, Mitchell G, Saunders C, Rahman B, Sousa MS, Barlow-Stewart K, Gleeson M, Tucker K.
    • Fam Cancer. 2015 Jun;14(2):265-72. doi: 10.1007/s10689-014-9770-z.
    • Personalization of loco-regional care for primary breast cancer patients (part 2).
    • Toi M, Winer EP, Benson JR, Inamoto T, Forbes JF, von Minckwitz G, Robertson JF, Grobmyer SR, Jatoi I, Sasano H, Kunkler I, Ho AY, Yamauchi C, Chow LW, Huang CS, Han W, Noguchi S, Pegram MD, Yamauchi H, Lee ES, Larionov AA, Bevilacqua JL, Yoshimura M, Sugie T, Yamauchi A, Krop IE, Noh DY, Klimberg VS; 2014 Kyoto Breast Cancer Consensus Conference.
    • Future Oncol. 2015 May;11(9):1301-5. doi: 10.2217/fon.15.66.
    • Breast cancer under age 40: a different approach.
    • Ribnikar D, Ribeiro JM, Pinto D, Sousa B, Pinto AC, Gomes E, Moser EC, Cardoso MJ, Cardoso F.
    • Curr Treat Options Oncol. 2015 Apr;16(4):334. doi: 10.1007/s11864-015-0334-8.
    • Review
    • Breast cancer version 2.2015.
    • Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Apr;13(4):448-75.
    • Practice Guideline, NCCN Clinical Practice Guidelines in Oncology
    • Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What's the Evidence? A Systematic Review with Meta-Analysis.
    • van den Broek AJ, Schmidt MK, van 't Veer LJ, Tollenaar RA, van Leeuwen FE.
    • PLoS One. 2015 Mar 27;10(3):e0120189. doi: 10.1371/journal.pone.0120189. eCollection 2015.
    • High expression of miR-214 is associated with a worse disease-specific survival of the triple-negative breast cancer patients.
    • Kalniete D, Nakazawa-Miklaševiča M, Štrumfa I, Āboliņš A, Irmejs A, Gardovskis J, Miklaševičs E.
    • Hered Cancer Clin Pract. 2015 Feb 8;13(1):7. doi: 10.1186/s13053-015-0028-z. eCollection 2015.
    • Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome.
    • Agarwal R, Liebe S, Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R, Rodon J, Kurzrock R, Subbiah V; Pan-Cancer Working Group.
    • Discov Med. 2014 Dec;18(101):331-9.
    • Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study.
    • Kataoka A, Tokunaga E, Masuda N, Shien T, Kawabata K, Miyashita M.
    • Breast Cancer. 2014 Nov;21(6):643-50. doi: 10.1007/s12282-013-0466-2. Epub 2013 Apr 16.
    • Opportunities and challenges of next-generation DNA sequencing for breast units.
    • Pilgrim SM, Pain SJ, Tischkowitz MD.
    • Br J Surg. 2014 Jul;101(8):889-98. doi: 10.1002/bjs.9458. Epub 2014 Mar 27.

    News

    Transforming Breast Cancer Care with NGS

    • Age-Related Decline in DNA Repair Function Explains Diminished Ovarian Reserve, Earlier Menopause, and Possible Oocyte Vulnerability to Chemotherapy in Women With BRCA Mutations.
    • Oktay K, Moy F, Titus S, Stobezki R, Turan V, Dickler M, Goswami S.
    • J Clin Oncol. 2014 Apr 1;32(10):1093-4. doi: 10.1200/JCO.2013.53.5369. Epub 2014 Feb 18.

    Chemotherapy-Induced Amenorrhea in Patients With Breast Cancer With a BRCA1 or BRCA2 Mutation.

    • Male Breast Cancer and Hyperestrogenemia: A Thirteen-Year Review.
    • Tariq KB, Al-Saffar F, Ibrahim S, Pham D, Farhangi A, Rana F, Zaiden R.
    • World J Oncol. 2014 Apr;5(2):55-61. doi: 10.14740/wjon803w. Epub 2014 May 6.
    • Newly Diagnosed with Breast Cancer: What You Need to Know.
    • Melinda Telli.
    • FORCE. Be Empowered Webinars. 2014 Mar 26.
    • Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer.
    • Maksimenko J, Irmejs A, Nakazawa-Miklasevica M, Melbarde-Gorkusa I, Trofimovics G, Gardovskis J, Miklasevics E.
    • Oncol Lett. 2014 Jan;7(1):278-284. Epub 2013 Nov 14.
    • BRCA1/2 and clinical outcome in a monoinstitutional cohort of women with hereditary breast cancer.
    • Sambiasi D, Lambo R, Pilato B, Tommasi S, Trojano G, Kardhashi A, Digennaro M, Trojano V, Simone G, Paradiso A.
    • Oncol Rep. 2014 Jan;31(1):365-9. doi: 10.3892/or.2013.2802. Epub 2013 Oct 22.
    • Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients.
    • Plakhins G, Irmejs A, Gardovskis A, Subatniece S, Liepniece-Karele I, Purkalne G, Teibe U, Trofimovics G, Miklasevics E, Gardovskis J.
    • Fam Cancer. 2013 Dec;12(4):683-9. doi: 10.1007/s10689-013-9646-7.
    • Chemotherapy-induced amenorrhea in patients with breast cancer with a BRCA1 or BRCA2 mutation.
    • Valentini A, Finch A, Lubinski J, Byrski T, Ghadirian P, Kim-Sing C, Lynch HT, Ainsworth PJ, Neuhausen SL, Greenblatt E, Singer C, Sun P, Narod SA.
    • J Clin Oncol. 2013 Nov 1;31(31):3914-9. doi: 10.1200/JCO.2012.47.7893. Epub 2013 Aug 26.

    Letter, Comment:

    Age-related decline in DNA repair function explains diminished ovarian reserve, earlier menopause, and possible oocyte vulnerability to chemotherapy in women with BRCA mutations.

    • Local approaches to hereditary breast cancer.
    • Cooper BT, Murphy JO, Sacchini V, Formenti SC.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii54-viii60. doi: 10.1093/annonc/mdt327.
    • Breast fine-needle aspiration cytology performance in the high-risk screening population: A study of BRCA1/BRCA2 mutation carriers.
    • Georgieva RD, Obdeijn IM, Jager A, Hooning MJ, Tilanus-Linthorst MM, van Deurzen CH.
    • Cancer Cytopathol. 2013 Oct;121(10):561-7. doi: 10.1002/cncy.21308. Epub 2013 May 29.
    • Breast cancer in adolescents and young adults: a review with a focus on biology.
    • Tichy JR, Lim E, Anders CK.
    • J Natl Compr Canc Netw. 2013 Sep 1;11(9):1060-9.
    • Review
    • Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients.
    • Mann RM, Bult P, van Laarhoven HW, Span PN, Schlooz M, Veltman J, Hoogerbrugge N.
    • Eur J Radiol. 2013 Sep;82(9):1416-22. doi: 10.1016/j.ejrad.2013.03.003. Epub 2013 Apr 6.

    Letter, Comment:

    Comparability versus statistical correctness.

    Letter, Comment:

    Good correlation does not automatically imply good agreement: the trouble with comparing tumour size by breast MRI versus histopathology.

    • BRCA Genetic Testing: An RN's Personal Story.
    • Wasserman L.
    • Clin J Oncol Nurs. 2013 Aug 1;17(4):449-50. doi: 10.1188/13.CJON.449-450.
    • Management of breast cancer in very young women.
    • Freedman RA, Partridge AH.
    • Breast. 2013 Aug;22 Suppl 2:S176-9. doi: 10.1016/j.breast.2013.07.034.
    • Review
    • Relapsed triple-negative breast cancer: challenges and treatment strategies.
    • Guarneri V, Dieci MV, Conte P.
    • Drugs. 2013 Aug;73(12):1257-65. doi: 10.1007/s40265-013-0091-6.
    • Review
    • The management of early-stage and metastatic triple-negative breast cancer: a review.
    • Anders CK, Zagar TM, Carey LA.
    • Hematol Oncol Clin North Am. 2013 Aug;27(4):737-49, viii. doi: 10.1016/j.hoc.2013.05.003. Epub 2013 Jun 18.
    • Body image in recently diagnosed young women with early breast cancer.
    • Rosenberg SM, Tamimi RM, Gelber S, Ruddy KJ, Kereakoglow S, Borges VF, Come SE, Schapira L, Winer EP, Partridge AH.
    • Psychooncology. 2013 Aug;22(8):1849-55. doi: 10.1002/pon.3221. Epub 2012 Nov 7.
    • Tumour diploidy and survival in breast cancer patients with BRCA2 mutations.
    • Tryggvadottir L, Olafsdottir EJ, Olafsdottir GH, Sigurdsson H, Johannsson OT, Bjorgvinsson E, Alexiusdottir K, Stefansson OA, Agnarsson BA, Narod SA, Eyfjord JE, Jonasson JG.
    • Breast Cancer Res Treat. 2013 Jul;140(2):375-84. doi: 10.1007/s10549-013-2637-4. Epub 2013 Jul 16.
    • Breast imaging in the young: the role of magnetic resonance imaging in breast cancer screening, diagnosis and follow-up.
    • Salem DS, Kamal RM, Mansour SM, Salah LA, Wessam R.
    • J Thorac Dis. 2013 Jun;5(Suppl 1):S9-S18. doi: 10.3978/j.issn.2072-1439.2013.05.02.
    • Molecular Mechanism and Targeted Therapy Options of Triple-Negative (ER, PgR, HER-2/neu) Breast Cancer: Review.
    • Kandula M, Ch KK, Ys AR.
    • World J Oncol. 2013 Jun;4(3):137-141. doi: 10.4021/wjon681e. Epub 2013 Jul 15.
    • Magnetic resonance imaging: value of diffusion-weighted imaging in differentiating benign from malignant breast lesions.
    • Stijven S, Gielen E, Bevernage C, Horvath M, Meylaerts L.
    • Eur J Obstet Gynecol Reprod Biol. 2013 Feb;166(2):215-20. doi: 10.1016/j.ejogrb.2012.10.029. Epub 2012 Dec 7.
    • Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.
    • Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y, Mackey JR, Damaraju S.
    • PLoS One. 2013;8(1):e53850. doi: 10.1371/journal.pone.0053850. Epub 2013 Jan 16.

    Press: Simple Blood Test Reveals DNA Marker That Predicts Breast Cancer Recurrence. (Medical News Today)

    • Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
    • Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.
    • Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.
    • [Choices for women at risk of hereditary breast cancer].
    • Saadatmand S, Obdeijn IM, Koppert LB, Tilanus-Linthorst M.
    • Ned Tijdschr Geneeskd. 2013;157(43):A6625.
    • Case report, Review, [Article in Dutch]
    • Surgical treatment differences among Latina and African American breast cancer survivors.
    • Campesino M, Koithan M, Ruiz E, Glover JU, Juarez G, Choi M, Krouse RS.
    • Oncol Nurs Forum. 2012 Jul;39(4):E324-31. doi: 10.1188/12.ONF.E324-E331.